A.P. Pharma raises $53.6mn to give long-acting granisetron a second NDA shot
This article was originally published in Scrip
Executive Summary
A.P. Pharma is raising $53.6 million through a common stock offering to new and existing institutional investors to see if the second time is the charm for APF530, a reformulated 5-HT3 antagonist in development to treat delayed- and acute-onset chemotherapy-induced nausea and vomiting (CINV), which the company sees as a $900 million-per-year market.
You may also be interested in...
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).